In this week's Homerun Slides, understanding the disorder of type 1 diabetes and a summary of glycemic recommendations.
Read More »37-Year-Old Hypertensive Drug Improves Beta Cell Function and Insulin Production
Researchers discover safe and effective therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset type 1.
Read More »Alcohol and Diabetes: How Alcohol Affects Diabetes
While there are a number of factors that can negatively impact adherence to self-care in a person with diabetes, this article will focus on diabetes and alcohol: specifically, on how alcohol consumption limits this adherence and affects the overall health of people with diabetes.
Read More »Poster Summaries of Interest at the 78th ADA Scientific Sessions
Key ADA poster summaries include liraglutide in type 1 diabetes, oral semaglutide, bottled water's association with type 2 diabetes, & SGLT-2 combo LIK066.
Read More »Abstracts of Interest at the 78th ADA Scientific Sessions
ADA 2018 abstracts of interest include Entresto for the Treatment of Diabetic Peripheral Neuropathy; Oral Contraceptive Associated with Postmenopausal Diabetes; Glucokinase as Adjunct Therapy in People with Type 1 Diabetes, and more.
Read More »Diabetes and Alcohol: A risk or a prevention?
There have been many studies that have been conducted meant to access the effect of alcohol consumption on diabetes - some suggesting that a moderate intake contributes to the risk for diabetes, and others suggesting moderate alcohol is a protective for type 2 diabetes.
Read More »New Closed-Loop Delivery System Improves Glycemic Control for People with T1D
Multi-center study compares closed-loop device to standard open-loop system in a home setting.
Read More »Liraglutide Plus Insulin for People with Type 1 Diabetes Improves Glycemic Control
One-year, randomized study shows lower HbA1c, blood glucose, blood pressure and body weight without significant increase in hypoglycemia.
Read More »Adding an SGLT-2 Inhibitor For Type 1 Diabetes
DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.
Read More »Six-Month Implantable Continuous Glucose Sensor Shows Accuracy In Type 1 Diabetes
The FDA approved the 90-day version of the implantable CGM Sensor.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.